- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
September 10, 2024Robins Kaplan Ranks Among Top Firms In 2024 American Lawyer Mid-Level Associates Survey
-
September 9, 2024Federal Judge Orders Transformative Reforms at West LA VA Campus in Major Victory for Disabled Veterans
-
September 9, 2024Robins Kaplan Partners Named to 2025 Lawdragon 500 Leading Litigators in America Guide
-
September 27, 2024Minnesota’s Largest Patent Jury Verdict: The Inside Story
-
October 9, 2024Perception vs. Reality in Trust and Estate Matters:
-
October 20, 2024License Agreement Disputes:
-
September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
-
August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
-
August 22, 2024Prior Art Takeaways From Fed. Circ. Public Disclosure Ruling
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New ANDA Cases
Spring 2014
Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Alcon Research, Ltd. v. Micro Labs Ltd., 14-0014 (D. Del.) |
Jan. 9, 2014 |
Hon. Sue L. Robinson |
Travatan Z® (travoprost ophthalmic solution) |
8,268,299 |
Biodelivery Sciences International, Inc. v. RB Pharma. Ltd., IPR2014-00325 (PTAB) |
Jan. 15, 2014 |
N/A |
Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride) |
8,475,832 |
Amneal Pharma., LLC v. Endo Pharma., Inc., IPR2014-00360 (PTAB) |
Jan. 16, 2014 |
N/A |
Opana® ER (oxymorphone hydrochloride extended-release tablets) |
8,329,216 |
Amneal Pharma., LLC v. Endo Pharma., Inc., IPR2014-00361 (PTAB) |
Jan. 16, 2014 |
N/A |
Opana® ER (oxymorphone hydrochloride extended-release tablets) |
8,309,122 |
Takeda Pharma. Co., Ltd. v. Mylan Inc., 14-0314 |
Jan. 21, 2014 |
Hon. Lucy H. Koh |
Dexilant® (dexlansoprazole delayed-release capsules) |
7,339,064 |
Lyne Labs., Inc. v. Lupin Ltd., 14-10153 (D. Mass.) |
Jan. 21, 2014 |
Hon. Nathaniel M. Gorton |
Phoslyra® (calcium acetate oral solution) |
8,591,938 |
Lyne Labs., Inc. v. Par Pharma., Inc., 14-10154 |
Jan. 21, 2014 |
Hon. Nathaniel M. Gorton |
Phoslyra® (calcium acetate oral solution) |
8,591,938 |
Millennium Pharma., Inc. v. Teva Pharma. USA, Inc., 14-0093 (D. Del.) |
Jan. 22, 2014 |
Hon. Gregory M. Sleet |
Velcade® (bortezomib injection) |
6,713,446 |
Cadence Pharma., Inc. v. Wockhardt Ltd., 14-0094 (D. Del.) |
Jan. 22, 2014 |
Hon. Leonard P. Stark |
Ofirmev® (acetaminophen solution) |
6,028,222 |
Eli Lilly and Co. v. Glenmark Generics Inc., USA, 14-0104 (S.D. Ind.) |
Jan. 23, 2014 |
Hon. Tanya W. Pratt |
Alimta® (pemetrexed disodium for injection) |
7,772,209 |
Eli Lilly and Co. v. Par Pharma. Cos., Inc., 14-0109 (S.D. Ind.) |
Jan. 23, 2014 |
Hon. Sarah E. Barker |
Effient® (prasugrel hydrochloride tablets) |
8,404,703 |
Cadence Pharma., Inc. v. Wockhardt Ltd., 14-0485 (D.N.J.) |
Jan. 23, 2014 |
Hon. Renee M. Bumb |
Ofirmev® (acetaminophen solution) |
6,028,222 |
AbbVie Inc. v. Roxane Labs., Inc., 14-0085 (S.D. Ohio) |
Jan. 23, 2014 |
Hon. Michael H. Watson |
Norvir® (ritonavir tablets) |
8,470,347 |
Eli Lilly and Co. v. Par Pharma. Cos., Inc., 14-0508 (D.N.J.) |
Jan. 24, 2014 |
Hon. Claire C. Cecchi |
Effient® (prasugrel hydrochloride tablets) |
8,404,703 |
Alcon Research, Ltd. v. Cipla Ltd., 14-0131 (S.D. Ind.) |
Jan. 29, 2014 |
Hon. Richard L. Young |
Pataday® (olopatadine hydrochloride ophthalmic solution) |
6,995,186 |
Novartis Pharma. Corp. v. Noven Pharma., Inc., 14-0111 (D. Del.) |
Jan. 30, 2014 |
Hon. Richard G. Andrews |
Exelon® Patch (rivastigmine transdermal system or extended release film) |
6,316,023 |
Sanofi-Aventis U.S. LLC v. Eli Lilly and Co., 14-0113 |
Jan. 30, 2014 |
Hon. Richard G. Andrews |
Lantus® / Lantus® SoloSTAR® (insulin glargine [rDNA origin] for injection) |
8,556,864 |
Teijin Ltd. v. Ranbaxy Labs., Ltd., 14-0117 (D. Del.) |
Jan. 31, 2014 |
Hon. Sue L. Robinson |
Uloric® (febuxostat tablets) |
6,225,474 |
Forest Labs., Inc. v. Teva Pharma. USA, Inc., 14-0121 (D. Del.) |
Jan. 31, 2014 |
Hon. Leonard P. Stark |
Namenda XR® (memantine hydrochloride extended-release capsules) |
5,061,703 |
Cephalon, Inc. v. Actavis LLC, 14-0122 (D. Del.) |
Jan. 31, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride) |
8,445,524 |
Senju Pharma. Co., Ltd. v. Lupin, Ltd., 14-0667 (D.N.J.) |
Jan. 31, 2014 |
Hon. Jerome B. Simandle |
Prolensa® (bromfenac ophthalmic solution 0.07%) |
8,129,431 |
Novartis Pharma. Corp. v. Dr. Reddy’s Labs., Ltd., 14-0157 (D. Del.) |
Feb. 5, 2014 |
Hon. Leonard P. Stark |
Gleevec® (imatinib mesylate capsules) |
6,894,051 |
Forest Labs., Inc. v. Glenmark Generics Inc., 14-0159 |
Feb. 6, 2014 |
Hon. Sue L. Robinson |
Savella® (milnacipran hydrochloride tablets) |
6,602,911 |
Fresenius Kabi USA, LLC v. Dr. Reddy’s Lab., Ltd., |
Feb. 6, 2014 |
Hon. Sue L. Robinson |
Diprivan® (propofol injectable emulsion) |
8,476,010 |
Fresenius Kabi USA, LLC v. Watson Labs., Inc. 14-0161 (D. Del.) |
Feb. 6, 2014 |
Hon. Sue L. Robinson |
Diprivan® (propofol injectable emulsion) |
8,476,010 |
Novartis Pharma. Corp. v. Dr. Reddy’s Labs., Ltd., 14-0785 (D.N.J.) |
Feb. 6, 2014 |
Hon. Claire C. Cecchi |
Gleevec® (imatinib mesylate capsules) |
6,894,051 |
Teijin Ltd. v. Hetero USA, Inc., 14-0166 (D. Del.) |
Feb. 7, 2014 |
Hon. Sue L. Robinson |
Uloric® (febuxostat tablets) |
6,225,474 |
Teijin Ltd. v. Lupin Ltd., 14-0184 (D. Del.) |
Feb. 12, 2014 |
Hon. Sue L. Robinson |
Uloric® (febuxostat tablets) |
6,225,474 |
Teijin Ltd. v. Roxane Labs., Inc., 14-0189 (D. Del.) |
Feb. 12, 2014 |
Hon. Sue L. Robinson |
Uloric® (febuxostat tablets) |
6,225,474 |
Merck Sharp & Dohme Corp. v. Xellia Pharma. APS, 14-0199 (D. Del.) |
Feb. 14, 2014 |
Hon. Richard G. Andrews |
Cancidas® (caspofungin acetate injection) |
5,952,300 |
Forest Labs., Inc. v. Apotex Corp., 14-0200 (D. Del.) |
Feb. 14, 2014 |
Hon. Leonard P. Stark |
Namenda XR® (memantine hydrochloride extended-release capsules) |
8,039,009 |
Salix Pharma., Inc. v. Novel Labs., Inc., 14-0213 (D. Del.) |
Feb. 18, 2014 |
Hon. Gregory M. Sleet |
Apriso® (mesalamine extended-release capsules) |
6,551,620 |
Otsuka Pharma. Co., Ltd. v. Torrent Pharma. Ltd., 14-1078 (D.N.J.) |
Feb. 18, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Merck Sharp & Dohme Corp. v. Xellia Pharma. APS, 14-0124 (W.D. Wis.) |
Feb. 18, 2014 |
Hon. Stephen L. Crocker |
Cancidas® (caspofungin acetate injection) |
5,952,300 |
AbbVie Inc. v. Aurobindo Pharma Ltd., 14-0215 |
Feb. 19, 2014 |
Hon. Gregory M. Sleet |
Zemplar® (paricalcitol injection) |
5,597,815 |
Meda Pharma. Inc. v. Perrigo Israel Pharma. Ltd., 14-1241 (D.N.J.) |
Feb. 25, 2014 |
Hon. Joel A. Pisano |
Astepro® (azelastine hydrochloride nasal spray) |
8,518,919 |
Sanofi v. Glenmark Generics Inc., USA, 14-0264 (D. Del.) |
Feb. 26, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
8,318,800 |
Sanofi v. Watson Labs., Inc., 14-0265 (D. Del.) |
Feb. 26, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
8,318,800 |
Takeda Pharma. USA, Inc. v. Watson Labs., Inc., 14-0268 (D. Del.) |
Feb. 27, 2014 |
Hon. Sue L. Robinson |
Colcrys® (colchicine, USP) |
7,601,758 |
Lyne Labs., Inc. v. Roxane Labs., Inc., 14-10460 |
Feb. 27, 2014 |
Hon. Nathaniel M. Gorton |
Phoslyra® (calcium acetate oral solution) |
8,591,938 |
Antares Pharma, Inc. v. Medac Pharma, Inc., 14-0270 (D. Del.) |
Feb. 28, 2014 |
Hon. Sue L. Robinson |
OtrexupTM (methotrexate injection) |
8,480,631 |
Bausch & Lomb Inc. v. Sandoz Inc., 14-1325 |
Mar. 2, 2014 |
Hon. Noel L. Hillman |
Bepreve® (bepotastine besilate 1.5% solution/drops) |
6,780,877 |
Novartis Pharma. Corp. v. Pharmaceutics Int’l, Inc., 14-1347 (D.N.J.) |
Mar. 3, 2014 |
Hon. Susan D. Wigenton |
Zometa® (zoledronic acid injection) |
8,324,189 |
Janssen Products, L.P. v. Lupin Ltd., 14-1370 |
Mar. 4, 2014 |
Hon. William H. Walls |
Prezista® (darunavir tablets) |
8,518,987 |
Roxane Labs., Inc. v. Camber Pharma., Inc., 14-0232 |
Mar. 4, 2014 |
Hon. Gregory L. Frost |
calcium acetate capsules |
8,563,032 |
Sanofi v. Alkem Labs. Ltd., 14-0292 (D. Del.) |
Mar. 6, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
7,323,493 |
Sanofi v. First Time US Generics LLC, 14-0293 |
Mar. 6, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
8,318,800 |
Sanofi v. Sun Pharma Global FZE, 14-0294 (D. Del.) |
Mar. 6, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
7,323,493 |
Allergan, Inc. v. Actavis PLC, 14-0188 (E.D. Tex.) |
Mar. 6, 2014 |
Hon. Rodney Gilstrap |
Restasis® (cyclosporine ophthalmic emulsion 0.05%) |
8,629,111 |
Medac Pharma., Inc. v. Antares Pharma., Inc., 14-1498 (D.N.J.) |
Mar. 7, 2014 |
Hon. Jerome B. Simandle |
OtrexupTM (methotrexate injection) |
8,664,231 |
Eli Lilly and Co. v. Accord Healthcare, Inc. USA, 14-0389 (S.D. Ind.) |
Mar. 12, 2014 |
Hon. Sarah Evans Barker |
Effient® (prasugrel hydrochloride tablets) |
5,288,726 |
Eli Lilly and Co. v. Accord Healthcare, Inc. USA, 14-1643 (D.N.J.) |
Mar. 13, 2014 |
Hon. Claire C. Cecchi |
Effient® (prasugrel hydrochloride tablets) |
5,288,726 |
Cephalon, Inc. v. Sun Pharma Global FZE, 14-0333 (D. Del.) |
Mar. 14, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride) |
8,609,863 |
Cephalon, Inc. v. Dr. Reddy’s Labs., Ltd., 14-0334 (D. Del.) |
Mar. 14, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride) |
8,609,863 |
Cephalon, Inc. v. Emcure Pharma Ltd., 14-0335 |
Mar. 14, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride) |
8,445,524 |
Sanofi v. Sun Pharma Global FZE, 14-1844 (N.D. Ill.) |
Mar. 14, 2014 |
Hon. Ruben Castillo |
Multaq® (dronedarone tablets) |
7,323,493 |
Astellas US LLC v. Emcure Pharma. USA, Inc., 14-1665 (D.N.J.) |
Mar. 14, 2014 |
Hon. Stanley R. Chesler |
Adenoscan® (adenosine injection) |
5,731,296 |
Otsuka Pharma. Co., Ltd. v. Amneal Pharma., LLC, 14-1688 (D.N.J.) |
Mar. 14, 2013 |
Hon. Mary L. Cooper |
Abilify® (aripiprazole oral solution) |
7,053,092 |
Pfizer Inc. v. Torrent Pharma. Ltd., 14-1704 (D.N.J.) |
Mar. 17, 2014 |
Hon. Mary L. Cooper |
Viagra® (sildenafil citrate tablets) |
6,469,012 |
Cephalon, Inc. v. Emcure Pharma Ltd., 14-1705 |
Mar. 17, 2014 |
Hon. Peter G. Sheridan |
Treanda® (bendamustine hydrochloride) |
8,445,524 |
Pfizer Inc. v. Torrent Pharma. Ltd., 14-1831 (S.D.N.Y.) |
Mar. 17, 2014 |
Hon. Paul A. Engelmayer |
Viagra® (sildenafil citrate tablets) |
6,469,012 |
Bristol-Myers Squibb Co. v. Apotex, Inc., 14-0351 |
Mar. 19, 2014 |
Hon. Richard G. Andrews |
Baraclude® (entecavir tablets) |
5,206,244 |
Sanofi v. Alkem Labs. Ltd., 14-1957 (N.D. Ill.) |
Mar. 19, 2014 |
Hon. Ruben Castillo |
Multaq® (dronedarone tablets) |
7,323,493 |
UCB, Inc. v. Corepharma, L.L.C., 14-1788 (D.N.J.) |
Mar. 20, 2014 |
Hon. Faith S. Hochberg |
Metadate CD® (methylphenidate hydrochloride capsules) |
6,344,215 |
ViiV Healthcare UK Ltd. v. Lupin Ltd., 14-0369 (D. Del.) |
Mar. 21, 2014 |
Hon. Richard G. Andrews |
Epzicom® (abacavir sulfate / lamivudine tablets) |
6,417,191 |
Bayer Pharma AG v. Watson Labs., Inc., 14-1804 (D.N.J.) |
Mar. 21, 2014 |
Hon. Jose L. Linares |
Staxyn® (vardenafil hydrochloride tablets) |
8,613,950 |
Novartis Pharma. Corp. v. Gland Pharma Ltd., 14-1841 (D.N.J.) |
Mar. 21, 2014 |
Hon. Susan D. Wigenton |
Reclast® (zoledronic acid injection) |
8,052,987 |
Bausch & Lomb, Inc. v. Akorn, Inc., 14-1866 (D.N.J.) |
Mar. 24, 2014 |
Hon. Noel L. Hillman |
Bepreve® (bepotastine besilate ophthalmic solution) |
6,780,877 |
Novartis Pharma. Corp. v. Dr. Reddy’s Labs., Ltd., 14-0387 (D. Del.) |
Mar. 26, 2014 |
Hon. Leonard P. Stark |
Gleevec® (imatinib mesylate capsules) |
RE43,932 |
Mallinckrodt LLC v. Amneal Pharma. LLC, 14-0389 |
Mar. 27, 2014 |
Hon. Richard G. Andrews |
Pennsaid® (diclofenac sodium topical solution) |
8,217,078 |
Bausch & Lomb, Inc. v. Micro Labs. Ltd., 14-1974 (D.N.J.) |
Mar. 28, 2014 |
Hon. Noel L. Hillman |
Bepreve® (bepotastine besilate ophthalmic solution) |
6,780,877 |
Bausch & Lomb, Inc. v. Apotex, Inc., 14-1975 (D.N.J.) |
Mar. 28, 2014 |
Hon. Noel L. Hillman |
Bepreve® (bepotastine besilate ophthalmic solution) |
6,780,877 |
Otsuka Pharma. Co., Ltd. v. Wockhardt Bio AG, 14-1979 (D.N.J.) |
Mar. 28, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Supernus Pharma. Inc. v. Actavis, Inc., 14-1981 (D.N.J.) |
Mar. 28, 2014 |
Hon. Renee M. Bumb |
Oxtellar XR™ (oxcarbazepine extended-release tablets) |
8,617,600 |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.